[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 840 Introduced in House (IH)]
<DOC>
116th CONGRESS
2d Session
H. RES. 840
Expressing support for the designation of the last day of February each
year as ``Rare Disease Day''.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
February 7, 2020
Mr. Carson of Indiana (for himself, Mr. Hudson, Mrs. Axne, Mrs. Beatty,
Mr. Bilirakis, Mrs. Brooks of Indiana, Mr. Butterfield, Mr. DeFazio,
Mr. Fitzpatrick, Ms. Lee of California, Mr. Malinowski, Ms. Matsui, Ms.
Roybal-Allard, Mr. Rush, and Mr. Visclosky) submitted the following
resolution; which was referred to the Committee on Energy and Commerce
_______________________________________________________________________
RESOLUTION
Expressing support for the designation of the last day of February each
year as ``Rare Disease Day''.
Whereas rare diseases and disorders are those which affect small patient
populations, typically populations smaller than 200,000 individuals in
the United States;
Whereas more than 7,000 rare diseases affect approximately 30,000,000 people in
the United States and their families;
Whereas children with rare diseases account for a significant proportion of the
population affected by rare diseases;
Whereas many rare diseases are serious, life-threatening, and lack an effective
treatment;
Whereas rare diseases and conditions cross the medical spectrum;
Whereas individuals with rare diseases experience challenges that include
difficulty in obtaining an accurate diagnosis, limited treatment
options, and difficulty finding physicians or treatment centers with
expertise in their disease;
Whereas although over 840 drugs and biologics have been approved for the
treatment of rare diseases by the Food and Drug Administration, millions
of people in the United States have rare diseases for which there is no
approved treatment;
Whereas lack of effective treatments and difficulty in obtaining reimbursement
for life-altering and often life-saving treatments remain significant
challenges for individuals with rare diseases and their families;
Whereas, as a result of the Orphan Drug Act, there have been important advances
in research of and treatment for rare diseases;
Whereas the Food and Drug Administration has taken great strides in gathering
patient perspectives to inform the drug review process as part of its
Patient-Focused Drug Development program, an initiative that was
reaffirmed under the Food and Drug Administration Reauthorization Act of
2017;
Whereas the 115th Congress passed a 10-year extension of the Children's Health
Insurance Program, ensuring coverage for many children with rare
diseases;
Whereas both the Food and Drug Administration and the National Institutes of
Health have established special offices to support and facilitate rare
disease research and treatments;
Whereas the National Organization for Rare Disorders, a nonprofit organization
established in 1983 to provide services to, and advocate on behalf of,
patients with rare diseases, remains a critical public voice for people
with rare diseases;
Whereas the National Organization for Rare Disorders sponsors ``Rare Disease
Day'' in the United States and partners with many other major rare
disease organizations to increase public awareness of rare diseases;
Whereas ``Rare Disease Day'' is observed each year on the last day of February;
Whereas ``Rare Disease Day'' was observed in the United States for the first
time on February 28, 2009, and observed in more than 100 countries in
2019; and
Whereas ``Rare Disease Day'' is expected to be observed globally in years to
come, providing hope and information for rare disease patients around
the world: Now, therefore, be it
Resolved, That the House of Representatives--
(1) supports the designation of ``Rare Disease Day'';
(2) recognizes the importance of improving awareness and
encouraging accurate and early diagnosis of rare diseases and
disorders; and
(3) supports a national and global commitment to improving
access to, and developing new treatments, diagnostics, and
cures for, rare diseases and disorders.
<all>